News | November 05, 2012

Paradise Renal Denervation System Shows 100% Response Rate at One-Year

Clinical trial of ultrasound-based renal denervation system shows it reduces resistant hypertension

Paradise System ReCor Medical Hypertension Therapies Renal Denervation

November 5, 2012 — ReCor Medical reported one-year follow-up data on patients who have been treated via renal denervation for their resistant hypertension with the company’s Paradise System — the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency energy. The data were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2012 by Peter Fitzgerald, M.D., Ph.D., associate professor of medicine (cardiology), associate professor of electrical engineering (by courtesy) and co-director of the Center for Research in Cardiovascular Interventions at Stanford University School of Medicine. Additionally, Fitzgerald serves as director of Core Cardiovascular Analysis Lab at Stanford.

The data showed that 100 percent (15/15) patients have responded favorably to their Paradise treatment. Three of these responders are now out to one-year follow-up. The accepted industry standard for a ‘responder’ is defined as >10 mm Hg systolic office blood pressure reduction. The scientific literature demonstrates that only a 5 mm Hg reduction in blood pressure results in a 14 percent decrease in stroke, a 9 percent decrease in heart disease and a 7 percent decrease in mortality.

“These preliminary clinical results, with all of the Paradise patients responding to treatment, are very compelling and dramatically underscore a significant competitive advantage for ReCor’s ultrasound-based Paradise?system compared to radiofrequency-based standard of care for treating resistant hypertension patients,” said Mano Iyer, CEO of ReCor Medical. “The benefit of our ultrasound approach is that Paradise is designed to simultaneously penetrate much deeper into the tissue, up to 10 mm, and heat circumferentially, to target all of the renal nerves in one location. Our unique approach is in stark contrast to radiofrequency, which is limited with its depth of penetration to just a few millimeters, as well as its inability to heat circumferentially in any given location. Data presented at TCT 2012 concluded that renal nerves are actually much further at depth than previously thought, and run circumferentially around the renal arteries, which underscores the Paradise ultrasound advantage.”

Paradise is approved for sale in Europe. It is not approved for sale or investigational use in the United States.

For more information: www.recormedical.com

Related Content

News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
Subscribe Now